Patent · US Active

Combination of azelastine and fluticasone for nasal administration

US9901585B2 · kind B2 · utility

11Cited by

120References

30Claims

0Family size

Assignee

Cipla Limited · IN

Inventors

Amar Lulla · Mumbai, IN
Geena Malhotra · Jamkhed, IN

Key dates

Filing date	Mar 15, 2016
Grant date	Feb 27, 2018
Priority date	—
Expiry date	Mar 15, 2036

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P37/08
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.